Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML
- 25 September 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (13) , 1625-1629
Abstract
The purpose of this study was to explore and determine the optimal landmark for defining complete remission after intensive induction therapy that best correlates with long-term survival outcome among patients with newly diagnosed acute myeloid leukemia.Keywords
This publication has 10 references indexed in Scilit:
- Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsLeukemia, 2024
- Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNBlood, 2022
- Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level AnalysesJournal of Clinical Oncology, 2021
- The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responsesBlood Reviews, 2021
- Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid LeukemiaClinical Lymphoma Myeloma and Leukemia, 2019
- Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center StudyJournal of Clinical Oncology, 2010
- Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studiesBritish Journal of Haematology, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEBBlood, 2000
- Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.Journal of Clinical Oncology, 1990